2014 Clinical Advances in Ovarian Cancer

2014 Clinical Advances in Ovarian Cancer

The Clearity Foundation

Cory Bentley, PhD

What has happened to the promising drugs that we have described in Clearity Survivor newsletters since 2010? Plenty. One has succeeded all the way to approval by the FDA. Several have shown anti-cancer activity in patients and continue to advance in clinical trials. Alas, some have failed. This article will highlight some of the most important developments in ovarian cancer treatment this year.

For the first time in 15 years, the FDA approved a new drug for patients who have platinum resistant disease. That drug is Avastin, which is anti-angiogenic; it works by interfering with new blood vessel formation – a key way for tumors to get nutrients as they grow. The phase III trial of Avastin, coined AURELIA, showed that the addition of Avastin improved both PFS (progression free survival) and ORR (overall response rate) compared to treatment with chemotherapy alone. (See the results for this trial and other trials testing anti-angiogenic treatments by clicking here).  Progression free survival (PFS) is the time from start of treatment until the tumor starts to grow. Overall response rate (ORR) is the percent of patients that show a partial response to treatment (some tumor shrinkage) or complete response (tumor no longer detectable). In this trial, Avastin was paired with a chemotherapy – Topotecan, Doxil, or Paclitaxel. Each pairing with Avastin led to an increased PFS of about two-fold compared to chemotherapy alone. A tumor blueprint can help guide the selection of one of these chemotherapeutic agents. In the future, there may also be a test that can predict if patients will respond to Avastin. At this year’s annual American Society of Clinical Oncology (ASCO) conference, researchers from Scotland reported that they had identified a tumor signature of Avastin response and studies to confirm those results are underway.

Another big story for ovarian cancer in 2014 relates to olaparib (Lynparza), a member of a class of drugs known as PARP inhibitors. Based on the review by European Medicines Agency in October, the European Union is expected to approve olaparib for the maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian cancer. Although the FDA chose not to approve this drug for use in the maintenance setting US based on the data from the phase II trial (they often wait for more rigorously performed phase III studies before approving a new drug), there is still optimism that PARP inhibitors will be therapeutic options in the US in the near future. The clinical trial results available for PARP inhibitors indicate that these drugs will be useful to treat patients with existing disease as well for those who are in remission. There are currently at least 20 ongoing clinical trials of PARP inhibitors either by themselves or combined with other drugs. Peruse them all by selecting PARP1/2 in the Molecular Target menu on the Clearity Foundation website.

Mutation in the BRCA1 or BRCA2 genes has been important in identifying patients that will respond to PARP inhibitors, but clinical trial evidence suggests that some patients without BRCA mutations may also respond. Now, Foundation Medicine has presented new data at a Symposium on Molecular Targets and Cancer Therapeutics in Barcelona (EORTC-NCI-AACR) molecularly identifying patients without BRCA mutations that are more likely to respond to the PARP inhibitor rucaparib. This molecular test may become a so-called companion diagnostic for rucaparib. Data from the PARP inhibitor, niraparib is also undergoing analysis for response predictors by Myraid Genetics using their companion diagnostic test that identifies tumors with deficiency in homologous recombination, something used by cells to repair harmful breaks in DNA. Clearity patients will recognize that the future availability of these types of tests that can add further detail to her tumor blueprint and provide important information for her treatment decisions. Positive trial data from PARP inhibitors along with the means to molecularly determine those women most likely to respond to them, sets the stage for this class of drugs to become an important option for ovarian cancer patients in the future.
The recent approval of Avastin and substantial progress in the clinical development of PARP inhibitors mark real progress being made against ovarian cancer in a field where progress has been so difficult. Clearity will continue to report on the development and approval of drugs that make a meaningful difference and offer true hope in our fight against ovarian cancer.
The information included in this newsletter is for educational purposes only. It is not intended nor implied that this information be a substitute for professional medical advice. You should always consult your healthcare provider to determine the appropriateness of the information for your own situation.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s